Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer.
about
Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC)Challenging the roles of CD44 and lipolysis stimulated lipoprotein receptor in conveying Clostridium perfringens iota toxin cytotoxicity in breast cancer.Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1)Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancerThe expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors.Phototheranostics of CD44-positive cell populations in triple negative breast cancer.Integrin-linked kinase as a novel molecular switch of the IL-6-NF-κB signaling loop in breast cancer.Proteomic profiling of lipid rafts in a human breast cancer model of tumorigenic progression.BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.Tumor-initiating cells and tumor vascularization.Hyaluronan metabolism in remodeling extracellular matrix: probes for imaging and therapy of breast cancer.Breast cancer stem cells: treatment resistance and therapeutic opportunities.Triple-negative breast cancer: investigating potential molecular therapeutic target.Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.Targeting p90 ribosomal S6 kinase eliminates tumor-initiating cells by inactivating Y-box binding protein-1 in triple-negative breast cancers.EPHB6 augments both development and drug sensitivity of triple-negative breast cancer tumours.
P2860
Q33796945-ADFE37D8-A18C-489E-B7A6-7E51713FE1EAQ33864348-E74A07BB-C88C-4BFE-A228-9B634BEA26F0Q34675192-D29AC93F-26F4-4A2C-A6DC-EEC6FBA5F6A6Q35832214-00C4BBF9-F12A-4895-B8C9-40CD997E5ED9Q36997962-8840AD3E-ADD5-4504-BB09-3E4D212132A1Q37006182-6B2ED4E2-5B13-4B2A-B878-743F964FC4C8Q37220527-8D339CDC-5C4B-4F32-AF55-397D913DDF0CQ37307440-487E32DF-BF50-4656-A827-6490DDB0580BQ37705790-FE203320-E470-4389-8231-3BB97F27D31DQ37827825-EE1A65C6-3370-4F32-A2CD-000CBED58C11Q37832163-454C5389-316A-4F2F-B72A-650C508B46C5Q37839530-B23606ED-898B-4FBD-A305-968258D07BDAQ38259322-69E4DB1E-B823-4E5C-85FB-5D9C7C76F27FQ39176046-05E12034-68BD-41EC-9031-EE1D5F93FF74Q39335656-D0F0200D-0648-45F3-9661-9C552354D37DQ52560135-8D59696F-40A0-425B-962B-7AB6F640E8A5
P2860
Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 July 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeting tumour-initiating ce ...... triple-negative breast cancer.
@en
Targeting tumour-initiating ce ...... triple-negative breast cancer.
@nl
type
label
Targeting tumour-initiating ce ...... triple-negative breast cancer.
@en
Targeting tumour-initiating ce ...... triple-negative breast cancer.
@nl
prefLabel
Targeting tumour-initiating ce ...... triple-negative breast cancer.
@en
Targeting tumour-initiating ce ...... triple-negative breast cancer.
@nl
P2093
P2860
P1476
Targeting tumour-initiating ce ...... triple-negative breast cancer
@en
P2093
Anna L Stratford
Kristen Reipas
Sandra E Dunn
P2860
P356
10.1017/S1462399410001535
P577
2010-07-26T00:00:00Z